The elected chartered accountant of Össur hf. is PricewaterhouseCoopers ehf.
Adress: Skógarhlíð 12, 105 Reykjavík
PricewaterhouseCoopers have been Össur’s auditor since 2022.
The Audit Commitee is composed of three Board Members. The majority of the Audit Committee shall be independent of the Company, the CEO and the Auditor. The Members of the Audit Committee shall possess the knowledge and expertise needed to perform the tasks of the Audit Committee. At least one Member of the Audit Committee shall have solid knowledge and experience in the field of financial statements or auditing.
Members of the Audit Committee
Master’s degree in Business Administration from the Copenhagen Business School in Denmark
Epos A/S (chairman)
Revenio Group Oyj (board member)
Interacoustics A/S (president)
Mr. Nielsen has spent his entire career with Demant A/S in various and expanding roles throughout the world. After working as an interim General Manager of Oticon Australia Pty Ltd. Mr. Nielsen assumed, in 1996, his current position as President of Diagnostics and Communications in Demant, which has operations worldwide.
Mr. Nielsen has no interest links with the Company’s main clients or competitors. Mr. Nielsen is employed by Demant A/S, whose largest shareholder is William Demant Invest A/S (the Company’s largest shareholder), and he is a dependent member of the Board.
Master’s degree (Pharm.) from Copenhagen University
Brunnur Investment Fund (chairman)
Coripharma Holding ehf (vice chairman)
Orf Genetics hf. (board member)
Florealis ehf. (chairman)
Vistor hf. (board member)
Saga Medica ehf. (board member)
Pretium ehf. (chairman)
Previous positions include President & EVP Strategic Projects of Actavis Plc in Iceland, a global integrated specialty pharmaceutical company; Deputy CEO and EVP Third Party Sales at Actavis Group hf.; Deputy CEO, Head of R&D, Assistant Managing Director, Development Manager, Regulatory Manager and Marketing Manager at Delta hf.; and Medical Representative at Pharmaco hf. She was the President of the European Generic Medicines Association from 2011-2013.
Ms. Eggertsdóttir has no interest links with the Company’s main clients or competitors. Ms. Eggertsdóttir is an independent member of the Board.
Dr. Esquenazi received his medical degree in Medicine and Surgery from Universidad Nacional Autonoma de Mexico. He completed his residency in PM&R at Temple University and a fellowship in gait analysis and prosthetic research at MossRehab. His research focuses on gait analysis, limb prosthetics, orthotics, spasticity management and robotics and technology in rehabilitation.
Past president of the American Academy of PM&R and member of the board of AMRPA and Einstein Healthcare Network.
Alberto Esquenazi, MD, serves as the John Otto Haas Chair of the Department of Physical Medicine and Rehabilitation at MossRehab, in Philadelphia and is the Chief Medical Officer as well as Director of the Gait and Motion Analysis Laboratory and Clinical Director of the Regional Amputee Center. He is Professor of PM&R at Jefferson School of Medicine. Dr. Esquenazi has published widely and is a member of national and international professional, educational, and research societies.
Dr. Esquenazi has no interest links with the Company‘s main clients, competitors or major shareholders. Dr. Esquenazi is an independent member of the Board.
The Audit Committee is only acting as an advisor to the Board and has no authority to take any decision on behalf of the Board. The Audit Committee shall operate in accordance with its Rules of Procedure. The principal duty of the Audit Committee is to ensure the quality of the Company‘s Consolidated Financial Statements and other financial information and the independence of the Company‘s Auditors. The Audit Committee holds 5 meetings a year. Information on the Audit Committee’s activities during the year can be found in Clause 3 in its Rules of Procedure.
Further information on the Members of the Audit Committee can be found on the Board of Directors‘ page.